^
Association details:
| Biomarker: | ALK fusion + MYC amplification + CCND1 deletion + FGFR3 deletion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
NGS-based liquid-biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step towards personalized NSCLC treatment
Published date:
05/31/2021
Excerpt:
We collected 26 plasma and two cerebrospinal fluid samples from 24 advanced ALK-positive NSCLC patients at disease progression to an ALK-I...Finally, a c-MYC gain, along with a loss of CCND1 and FGFR3, were detected in a patient progressing on a first-line treatment with crizotinib.
DOI:
https://doi.org/10.1002/1878-0261.13033
